Rivoglitazone

Summary

Rivoglitazone (CHEMBL2104753) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including type 2 diabetes mellitus and dry eye syndrome.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 5
• Chemistry: 397.4 Da · C20H19N3O4S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2104753
Name	Rivoglitazone
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	3055168
Molecular formula	C20H19N3O4S
Molecular weight	397.4
InChIKey	XMSXOLDPMGMWTH-UHFFFAOYSA-N

SMILES: CN1C2=C(C=CC(=C2)OC)N=C1COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4

IUPAC name: 5-[[4-[(6-methoxy-1-methylbenzimidazol-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione

Also known as: CS-011, DE-101, R 106056, R-106056, Rivoglitazona, Rivoglitazone, RIVOGLITAZONE

Parent form; salt/anhydrous children: CHEMBL3526905, CHEMBL3526906, CHEMBL3527103

Patent coverage: 599 distinct patent families (1,655 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Peroxisome proliferator-activated receptor gamma.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PPARG	7.37	EC50	43	nM	CHEMBL_ACT_18444275

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
type 2 diabetes mellitus	3	MONDO:0005148	MONDO:0005148
dry eye syndrome	2	MONDO:0006733	EFO:1000906

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE3	2
PHASE2	2
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00143520	PHASE2/PHASE3	COMPLETED	Placebo and Active Controlled Study of Rivoglitazone in Type 2 Diabetes
NCT00484198	PHASE3	COMPLETED	Study of Rivoglitazone in Type 2 Diabetes Mellitus
NCT00571519	PHASE3	TERMINATED	Randomized, Double-blind, Active-controlled, Study of Rivoglitazone in Type 2 Diabetes Mellitus
NCT00575471	PHASE2	COMPLETED	Placebo Controlled Dose-Response Study of Rivoglitazone in Type 2 Diabetes
NCT00575874	PHASE2	COMPLETED	Placebo and Active Comparator Controlled Dose Response Study of Rivoglitazone in Type 2 Diabetes

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).